Management of Major Depressive Disorder

Initial Assessment and Cross-Titration

Confirm inadequate response to sertraline plus Rexulti combination, defined as less than 50% reduction in depressive symptoms after 6-8 weeks of adequate dosing, and document baseline symptoms, side effects, and vital signs, as recommended by the American College of Physicians 1
Implement a cross-titration approach with a 1-2 week overlap period, starting Vraylar at 1.5 mg/day while maintaining current Rexulti dose, to minimize withdrawal effects and maintain therapeutic efficacy, according to the American College of Physicians 1

Maintain stable sertraline dosing throughout the transition period, with standard therapeutic dosing of 50-200 mg/day, as recommended by the American College of Physicians 1

Assess patient status, therapeutic response, and adverse effects within 1-2 weeks of initiating the medication change, and monitor weekly during the cross-titration period, according to the American College of Physicians 1
Monitor parameters such as depressive symptoms, emergence of akathisia, metabolic parameters, extrapyramidal symptoms, and suicidal thoughts, which is a high risk during the first 1-2 months of treatment changes, as recommended by the American College of Physicians 1
Patients should be monitored closely for emergence of suicidal thoughts, especially in the first 1-2 months, as recommended by the National Institute of Mental Health and the American Medical Association 1

Evaluate response to the new regimen within 6-8 weeks of completing the transition, and consider alternative augmentation strategies or switching approaches if inadequate response after 8 weeks of optimized Vraylar dosing, as recommended by the American College of Physicians 1
Consider switching to another SSRI (e.g., sertraline), an SNRI (e.g., venlafaxine), or bupropion if inadequate response, with similar efficacy rates of approximately 20-25% remission after switching, as supported by the American Psychiatric Association with moderate-quality evidence 2
For patients with anxiety symptoms, sertraline or venlafaxine may be preferred due to their established efficacy in anxiety disorders, according to the American Academy of Child and Adolescent Psychiatry and Neuropsychopharmacology 3, 4
Bupropion is associated with less sexual dysfunction and somnolence than SSRIs, and may cause different side effects such as headache, insomnia, and agitation, as noted by the American College of Physicians 1
Paroxetine has higher rates of sexual dysfunction compared to other SSRIs, and should be considered when switching from bupropion to an SSRI due to efficacy concerns, according to the American College of Physicians 1

For older adults, preferred agents include citalopram, escitalopram, sertraline, mirtazapine, venlafaxine, and bupropion, and paroxetine and fluoxetine should be avoided due to higher adverse effect rates, as recommended by the American Academy of Family Physicians 5
Treatment response assessment should consider how the switch might affect comorbid anxiety, insomnia, or other conditions, as recommended by the American Gastroenterological Association and the National Institute of Mental Health 1, 6